Odonate Therapeutics (ODT) PT Lowered to $4 at Goldman Sachs, Following Important Clinical Update
Tweet
Share
E-mailGet Alerts ODT Hot Sheet
Price: $1.12 --0%
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 12
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 12
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi lowered the price target on Odonate Therapeutics (NASDAQ: ODT) to $4.00 (from $11.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Upgrades SL Green Realty (SLG) to Outperform, 'NYC Is Back (Even Office)'
- Commerzbank AG (CBK:GR) (CRZBY) PT Raised to EUR17.90 at UBS
- ASOS Plc. (ASC:LN) (ASOMY) PT Lowered to GBP3.60 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
